

Hemovigilance Module Adverse Reaction Acute Hemolytic Transfusion Reaction

*Required for saving *Facility ID#: _____ NHSN Adverse Reaction #: Patient Information *Date of Birth: ____/___ *Patient ID: *Sex: ☐M ☐F Secondary ID: Social Security #: Medicare #: First Name: Middle Name: Last Name: Not Hispanic or Latino Unknown Ethnicity (Specify): Hispanic or Latino Declined to respond American Indian or Asian Black or African Middle Eastern or North Race (Select all that Alaska Native American African apply): Unknown Declined to respond Pacific Islander Interpreter Needed: Yes \square No Preferred Language (Specify from the list provided):_____ Declined to Respond Unknown *Blood Group: ☐ A- ☐ A+ ☐ B- ☐ B+ ☐ AB-☐ AB+ □ 0-□ 0+ ☐ Blood type not done ☐ Transitional ABO / Rh + ☐ Transitional ABO / Rh -☐ Transitional ABO / Transitional Rh ☐ Group A/Transitional Rh ☐ Group B/Transitional Rh ☐ Group O/Transitional Rh ☐ Group AB/Transitional Rh **Patient Medical History** List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions) Code: Description: Code: Description: Description: Code: List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions) Code: Description: Code: _____ Description: Code: Description: List the patient's comorbid conditions at the time of the transfusion related to the adverse ☐ UNKNOWN reaction. (Use ICD-10 Diagnostic codes/descriptions) NONE Code: _____ Description: Code: _____ Description: Code: _____ Description:

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.307 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 22 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



| List the patient's relevant medical procedure including past procedures and procedures to be UNKNO | NWC |
|--|---------|
| performed during the current hospital or outpatient stay. (Use ICD-10 Procedure codes/descriptions) | |
| Code: Description: | |
| Code: Description: | |
| Code: Description: | |
| Additional Information | |
| Transfusion History | |
| Has the patient received a previous transfusion? | |
| Blood Product: | ocyte |
| Date of Transfusion:// UNKNOWN | |
| Was the patient's adverse reaction transfusion-related? ☐ YES ☐ NO | |
| If yes, provide information about the transfusion adverse reaction. | |
| Type of transfusion adverse reaction: | R |
| ☐ HTR ☐ TTI ☐ PTP ☐ TACO ☐ TAD ☐ TA-GVHD ☐ TRALI ☐ UNKNO | OWN |
| OTHER Specify | |
| Reaction Details | |
| *Date reaction occurred:/ *Time reaction occurred: : | |
| Facility location where patient was transfused: | |
| s this reaction associated with an incident? | |
| | |
| nvestigation Results | |
| nvestigation Results Calcute hemolytic transfusion reaction (AHTR) | |
| | _ |
| Acute hemolytic transfusion reaction (AHTR) | - |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) | |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition | t: |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onser | t: |
| Acute hemolytic transfusion reaction (AHTR) Immune | t: |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure | t: |
| Acute hemolytic transfusion reaction (AHTR) Immune | t:) |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure | t:) |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure Check all that apply: Decreased fibrinogen Decreased haptoglobin Elevated bilirubin Elevated LDH Hemoglobinemia Hemoglobinuria Plasma discoloration c/w hemolysis Spherocytes on blood film Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3 | t:) |
| Acute hemolytic transfusion reaction (AHTR) Immune | t:) |
| Acute hemolytic transfusion reaction (AHTR) Immune | t:) |
| *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure Check all that apply: Decreased fibrinogen Decreased haptoglobin Elevated bilirubin Elevated LDH Hemoglobinemia Hemoglobinuria Plasma discoloration c/w hemolysis Spherocytes on blood film Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3 Positive elution test with alloantibody present on the transfused red blood cells Serologic testing is negative, and physical cause (e.g., thermal, osmotic, mechanical, chemical) is confirmed. | t:) |
| *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure Check all that apply: Decreased fibrinogen Decreased haptoglobin Elevated bilirubin Elevated LDH Hemoglobinemia Hemoglobinuria Plasma discoloration c/w hemolysis Spherocytes on blood film Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3 Positive elution test with alloantibody present on the transfused red blood cells Serologic testing is negative, and physical cause (e.g., thermal, osmotic, mechanical, chemical) is confirmed. Physical cause is excluded but serologic evidence is not sufficient to meet definitive criteria. | t:) |
| *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure Check all that apply: Decreased fibrinogen Decreased haptoglobin Elevated bilirubin Elevated LDH Hemoglobinemia Hemoglobinuria Plasma discoloration c/w hemolysis Spherocytes on blood film Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3 Positive elution test with alloantibody present on the transfused red blood cells Serologic testing is negative, and physical cause (e.g., thermal, osmotic, mechanical, chemical) is confirmed. Physical cause is excluded but serologic evidence is not sufficient to meet definitive criteria. | t:) |
| Acute hemolytic transfusion reaction (AHTR) Immune Antibody: Non-immune (specify) *Case Definition Check the following that occurred during, or within 24 hours of cessation of transfusion with new onset Back/flank pain Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC) Oliguria/anuria Hypotension Fever Hematuria (gross visual hemolysis) Pain and/or oozing at IV site Renal failure Check all that apply: Decreased fibrinogen Decreased haptoglobin Elevated bilirubin Elevated LDH Hemoglobinemia Hemoglobinuria Plasma discoloration c/w hemolysis Spherocytes on blood film Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3 Positive elution test with alloantibody present on the transfused red blood cells Serologic testing is negative, and physical cause (e.g., thermal, osmotic, mechanical, chemical) is confirmed. Physical cause is excluded but serologic evidence is not sufficient to meet definitive criteria. Physical cause is suspected and serologic testing is negative. AHTR is suspected, but symptoms, test results, and/or information are not sufficient to confirm reacti | t:) |



| SAFETT NETWORK | | | | | www.cuc.gov/misn | 1 | |
|---|---|---------------------|----------------|----------------|--------------------|----|--|
| Cutaneous: | Edema | ☐ Flushin | g | ☐ Jaund | dice | | |
| | Other rash | ☐ Pruritus | s (itching) | Urtica | aria (hives) | | |
| Hemolysis/Hemorrhage: | ☐ Hemoglobinemia | a Dositive | e antibody scr | reen | | | |
| Pain: | Abdominal pain | | | | | | |
| Respiratory: | ☐ Bilateral infiltrate☐ Shortness of bre | - | ☐ Bronchos | • |] Cough | | |
| Other: (specify) | | | | | | _ | |
| *Severity | | | | | | | |
| Did the patient receive or ex | perience any of the f | ollowing? | | | | | |
| ☐ No treatment require | ed | ☐ Symptomat | ic treatment o | only | | | |
| ☐ Hospitalization, inlcu | ding prolonged hosp | italization | Life | -threatening | reaction | | |
| ☐ Disability and/or inca | pacitation | ☐ Congenital | anomaly or bi | irth defect(s) | of the fetus | | |
| Other medically impo | ortant conditions | Death | ☐Unk | known or not | t stated | | |
| *Imputability | | | | | | | |
| Which best describes the rela | ationship between th | e transfusion and | the reaction? | ? | | | |
| ☐ ABO or other allotypic | RBC antigen incomp | atibility is known. | | | | | |
| Only transfusion-related (i.e., immune or non-immune) cause of acute hemolysis is present. | | | | | | | |
| There are other potent likely cause. | ial causes present th | at could explain a | acute hemolys | sis, but trans | sfusion is the mos | st | |
| Other causes of acute hemolysis are more likely, but transfusion cannot be ruled out. | | | | | | | |
| Evidence is clearly in favor of a cause other than the transfusion, but transfusion cannot be excluded. | | | | | | | |
| ☐ There is conclusive evidence beyond reasonable doubt of a cause other than the transfusion. | | | | | | | |
| ☐ The relationship between the adverse reaction and the transfusion is unknown or not stated. | | | | | | | |
| Did the transfusion occur at y | our facility? | YES N | 0 | | | | |
| Module-generated Designa | ations | | | | | | |
| NOTE: Designations for case de application based on responses | | | | | d in the NHSN | | |
| *Do you agree with the <i>ca</i> | <u>ise definition</u> desigi | nation? | | YES | □ NO | | |
| ^Please indicate your desig | ınation | | | | | - | |
| * Do you agree with the <u>se</u> ^Please indicate your desig | | • | |] YES | □NO | _ | |
| *Do you agree with the <u>im</u> | <u>n<i>putability</i></u> designati | ion? | | YES | □NO | | |
| ^Please indicate your desig | nation | | | | | - | |
| Patient Treatment | | | | | | | |
| Did the patient receive treatm | ent for the transfusio | n reaction? | ☐ YES | ☐ NO | UNKNOWN | | |
| If yes, select treatment(s): | | | | | | | |
| ☐ Medication (Select the | type of medication) | | | | | | |
| ☐ Antipyretics ☐ | Antihistamines | Inotropes/Vasop | ressors 🔲 ! | Bronchodilat | tor 🗌 Diureti | cs | |
| ☐ Intravenous Immunoglobulin ☐ Intravenous steroids ☐ Corticosteroids ☐ Antibiotics | | | | | | | |
| ☐ Antithymocyte gl | lobulin | porin 🗌 C | Other | | | | |
| ☐ Volume resuscitation (| (Intravenous colloids | or crystalloids) | | | | | |



| ☐ Res | piratory support <i>(Sele</i>] Mechanical ventilati | | |) e ventilation | ☐ Oxygen | | | | |
|-------------------------------------|---|---------------------------------------|----------------------------|----------------------|-----------------|---------------------------------|-----------------|------------------------|-------|
| ☐ Ren | al replacement therap] Hemodialysis 🏻 🏻 F | · · | | | o-Venous Hemo | filtratio | on | | |
| ☐ Phle | botomy er Specify: | | | | | | | | |
| Outcome | Outcome | | | | | | | | |
| Cause o | | • | sion to | death: | Minor or no seq | uelae | _ | t determ | |
| Component | | | | | | | | | |
| *Was a partion? | cular unit implicated | d in (i.e., respo | | | idverse [| Yes | s 🗆 | No [|] N/A |
| Transfusion Start and End Date/Time | *Component code (check system used) | Amount transfused at reaction onset | ransfused at Infection and | | | *Blood group ated of unit Unit? | | | ated |
| ^IMPLICATED | UNIT | | | | | | | | |
| : | ☐ ISBT-128 ☐ Codabar | ☐ Entire unit ☐ Partial unit mL | | | // : | □ A- □B+ □ O- | □ A+ □ AB- □ O+ | □ B- □ AB+ □ N/A | Y |
| // : | ☐ ISBT-128 ☐ Codabar ———————— | ☐ Entire unit ☐ Partial unit mL | | . — — — . — — — — | :: | □ A- □B+ □ O- | □ A+ □ AB- □ O+ | □ B- □ AB+ □ N/A | N |
| Custom Field | ds | | | | | | | | |
| Label | | | | Label | | | | | |
| | | / | - | | | | / | / | |
| Comments | | | | | | | | | |
| | | | | | | | | | |